Pharmaceutical Research and Manufacturers of America Fnd Inc.

“The chief operating officer of the pharmaceutical research and manufacturers of america (phrma), a section 501(c)(6) trade association that has a historic and continuing relationship with the foundation, is an ex-officio member of the foundation's board of directors. Foundation directors must be research and development executives or chief medical officers of companies that are members of phrma, but are elected by the foundation board itself.”

“The foundation form 990 is prepared by bdo usa, cpas, and reviewed internally by key financial management and the foundation's president. A copy of the 990 is provided to the board of directors to review prior to filing.”

“All directors, officers and key employees of the foundation must report potential and actual conflicts as they arise. In addition, they are required to sign an annual conflict of interest disclosure statement. When a potential conflict of interest is disclosed to, or otherwise comes to the attention of, the president, the chair of the board or an on-affected director, he or she shall consider all the relevant circumstances and shall determine whether the arrangement is potentially harmful to the best interests of the foundation. If the arrangement is found not to be harmful, then the arrangement may be authorized or approved; otherwise, the director, officer or key employee who is involved or expects to be involved in the arrangement shall be notified that the arrangement is not authorized or approved and, if already in existence, should be terminated. The president shall authorize or approve an arrangement only after consulting with the chair of the board. The chair of the board shall authorize or approve an arrangement only upon a vote of a majority of uninvolved directors.”

“Merit raises and bonuses are determined in accordance with phrma policy based on staff evaluations, and recommendations are forwarded to the president for review. Overall performance of the president of the foundation, including merit raises and bonuses, is also determined in accordance with phrma policy based on staff evaluations by the ex-officio member of the foundation board. This evaluation is forwarded as are recommendation to the chairman and vice chair of the foundation board for final approval of the president's performance, including compensation/bonus.”

“The foundation does not make its governing documents or financial statements available to the public.”

“Description of organization mission the phrma foundation works to improve public health by proactively investing in innovative research, education and value-driven health care.”

“Digital health technologies: supports research on the use of dhts in underrepresented populations in clinical trials to advance fda regulatory decision making.”

“The two separate value assessment and health outcomes research programs were combined to create one program named value assessment-health outcomes research. Minor grants will be paid out through 2024, but all expenses will be reported under new program. Pharmaceutics, informatics, and pharmacology/toxicology programs also ended.”

“TRANSLATIONAL MEDICINE - SUPPORTS EARLY CAREER INVESTIGATORS CONDUCTING NOVEL RESEARCH THAT USES THE "BEDSIDE TO BENCH" APPROACH TO ADDRESS UNMET NEEDS IN THE DIAGNOSIS, TREATEMENT, AND PREVENTION OF DISEASE. EXPENSES $ 621,230. GRANTS $ 492,440. REVENUE $ 0. DIGITAL HEALTH TECHNOLOGIES: SUPPORTS RESEARCH ON THE USE OF DHTs IN UNDERREPRESENTED POPULATIONS IN CLINICAL TRIALS TO ADVANCE FDA REGULATORY DECISION MAKING. EXPENSES $ 218,716. GRANTS $ 175,000. REVENUE $ 0. OTHER PROGRAMS EXPENSES $ 89,289. GRANTS $ 11,000. REVENUE $ 0.”

“GRANT REFUNDS $37,734”

“The audit oversight process has not changed from the prior year.”